Within minutes of a stroke, a severe reduction of blood flow and oxygen supply causes cell death (red) in the brain tissue surrounding the blocked blood vessel. In the immediate vicinity of the dead tissue is a hypoxic zone (green), termed the penumbra, that consists of tissue that is severely deprived of oxygen and at risk of dying. Until the occlusion is treated, the oxygen-deprived tissue in the penumbra dies (growing red area in the top schematic), resulting in neurological impairments (i.e. in speech, motor control, and cognitive function). By delivering oxygen to brain tissue affected by stroke, Omniox’s drug candidate OMX-201 delays or prevents this progressive brain tissue death, potentially saving brain tissue (blue area in the bottom schematic) and preserving brain function until recanalization of the blocked blood vessel using current Standard of Care (SOC) therapies (i.e. mechanical thrombectomy or Activase©/tPA) can be performed.
The hypoxic tumor microenvironment suppresses anti-cancer immune responses by modulating multiple signaling pathways including, but not limited to, hypoxia-inducible factor (HIF-1) signaling.
Hypoxia has been shown through HIF-1 signaling to:
By delivering oxygen to the hypoxic tumor microenvironment, OMX reverses these effects and stimulates an immune attack on tumor cells resulting in tumor cell death.